Upadacitinib Was Efficacious and Well Tolerated Over 30 Months in Patients with Crohn ’s Disease in the CELEST Extension Study

The long-term efficacy and safety of upadacitinib was evaluated in an open-label extension (OLE) of a phase 2, double-blind, randomized trial of patients with Crohn ’s disease (CD).

Source: Clinical Gastroenterology and Hepatology - December 26, 2021 Category: Gastroenterology Authors: Geert D ’Haens, Julian Panés, Edouard Louis, Ana Lacerda, Qian Zhou, John Liu, Edward V. Loftus Source Type: research